Want to join the conversation?
$PRGO's Rx Pharmaceuticals segment posted 34% net sales growth due to increase in existing product sales & strong new product launches. Adjusted margins were unchanged due to continued investments in R&D and in its specialty pharma sales force. Specialty Sciences net sales were $85MM in 3Q15 and were essentially flat on a constant currency basis.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.